Company news
Janux Therapeutics, Inc. news in 2022
Janux Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
December 26, 2022
Janux Therapeutics to Present at Upcoming Investor Conferences in November
November 21, 2022
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 9, 2022
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
October 11, 2022
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
September 22, 2022
Janux Therapeutics Appoints Winston Kung to Board of Directors
September 21, 2022
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
August 30, 2022
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 8, 2022
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
June 1, 2022
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
May 30, 2022
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 9, 2022
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
April 25, 2022
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 17, 2022
Janux Therapeutics to Present at Upcoming March Investor Conferences
February 28, 2022
Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer
February 28, 2022
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
January 4, 2022